↑ 疾患リストへ ← 戻る

 76. 下垂体性ゴナドトロピン分泌亢進症 [臨床試験数:20,薬物数:32(DrugBank:7),標的遺伝子数:2,標的パスウェイ数:6] 

Searched query = "Pituitary gonadotropin secretion hyperthyroidism", "Gonadotropin secreting pituitary adenoma", "Central precocious puberty", "Gonadotropin producing pituitary adenoma"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03963752June 1, 20193 June 2019Clinical Trial of Rapid Progressive Central Precocious Puberty With Integrative Chinese and Western MedicineEvidence-based Medical Research on the Treatment of Children's Rapid Progressive Central Precocious Puberty With Integrative Chinese and Western MedicineIdiopathic Precocious PubertyDrug: Ziyinxiehuo granules Herbs;Drug: Megestrol Acetate Tablet;Drug: Leuprorelin Acetate 3.75mg InjectionChildren's Hospital of Fudan UniversityNot recruiting5 Years8 YearsFemale164Phase 4
2NCT03695237October 24, 20184 November 2019A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Leuprolide Acetate 45mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)A Phase 3, Multicenter, Open-Label, Two-Part Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Leuprolide Acetate 45mg 6-Month Depot Formulation in Children With Central Precocious Puberty (CPP)Central Precocious Puberty (CPP)Drug: Leuprolide Acetate (LA)AbbVieRecruiting2 Years11 YearsAll40Phase 3United States;Puerto Rico
3NCT02993926June 24, 201718 December 2018A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty (CPP) Among Chinese ParticipantsAn Observational, Retrospective Study to Evaluate the Long Term Safety and Effectiveness of Leuprorelin in the Treatment of Central Precocious PubertyPuberty, PrecociousDrug: LeuprorelinTakedaNot recruitingN/AN/AAll108Phase 3China
4NCT02811471June 20164 July 2016Pharmacokinetic Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious PubertyAn Open-label, Single Arm, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Leuprolide Acetate 45 mg for Injectable Suspension Controlled Release in Subjects With Central (Gonadotropin-Dependent) Precocious Puberty—Part A and BCentral Precocious PubertyDrug: LeuprolideNemours Children's ClinicTolmar Inc.Recruiting2 Years9 YearsBoth5Phase 3United States
5NCT02974270June 20165 December 2016Analysis of Body Mass Index in Central Precocious Puberty Patients Treated With Leuprolide AcetateAnalysis of Body Mass Index in Central Precocious Puberty(CPP) Patients Treated With Leuprolide AcetatePrecocious Puberty, CentralDrug: LeuprolideKyungpook National UniversityRecruitingN/A9 YearsBoth100Phase 4Korea, Republic of
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT02452931August 31, 201515 July 2019Pharmacokinetic Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious PubertyAn Open-label, Single Arm, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Leuprolide Acetate 45 mg for Injectable Suspension Controlled Release in Subjects With Central (Gonadotropin-Dependent) Precocious PubertyPrecocious Puberty, CentralDrug: Leuprolide Acetate 45 mgTolmar Inc.Not recruiting2 Years9 YearsAll64Phase 3United States;Argentina;Canada;Chile;Mexico;New Zealand
7NCT02427958August 11, 201510 December 2018A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese PatientsAn Open Label, Multicenter Study to Assess the Safety and Efficacy of Leuprorelin in the Treatment of Central Precocious PubertyPuberty, PrecociousDrug: LeuprorelinTakedaNot recruiting1 Year9 YearsAll300Phase 4China
8NCT03316482June 11, 201516 December 2017Leuprorelin Acetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious PubertyA Multicenter, Open, Prospective Study to Evaluate the Safety and Efficacy of Leuprorelin Acetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious PubertyCentral Precocious PubertyDrug: Leuplin DPS 11.25mgJin Soon HwangRecruiting4 Years9 YearsAll68Phase 4Korea, Republic of
9EUCTR2014-004493-42-Outside-EU/EEA8 December 2014A clinical trial to determine safety and efficacy of Leuprolide Acetate 11.25mg and 30mg in children with central premature pubertyA Phase 3, Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy and Safety of Leuprolide Acetate 11.25 and 30 mg Formulations in Children with Central Precocious PubertyCentral Precocious Puberty
MedDRA version: 17.1 Level: LLT Classification code 10073186 Term: Central precocious puberty System Organ Class: 100000004860 ;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Trade Name: trade name depends on the source of the product
Product Name: Leuprolide acetate depot
Pharmaceutical Form: Suspension for injection in pre-filled syringe
INN or Proposed INN: LEUPRORELIN ACETATE
CAS Number: 74381-53-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 11.25-
Trade Name: trade name depends on the source of the product
Pharmaceutical Form: Suspension for injection in pre-filled syringe
INN or Proposed INN: LEUPRORELIN ACETATE
CAS Number: 74381-53-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 30-
Abbvie previously known as AbbottNot AvailableFemale: yes
Male: yes
80Phase 3United States;Puerto Rico
10EUCTR2014-004494-16-Outside-EU/EEA8 December 2014A clinical trial to determine safety and efficacy of Leuprolide Acetate 11.25mg and 30mg in children with central premature pubertyA 36 Month, Multi-Center, Open-Label Extension Study to Evaluate the Safety of Leuprolide Acetate 11.25 mg and 30 mg Formulations in Children with Central Precocious PubertyCentral Precocious Puberty
MedDRA version: 17.1 Level: LLT Classification code 10073186 Term: Central precocious puberty System Organ Class: 100000004860 ;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Trade Name: trade name depends on the source of the product
Pharmaceutical Form: Suspension for injection in pre-filled syringe
INN or Proposed INN: LEUPRORELIN ACETATE
CAS Number: 74381-53-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 11.25-
Trade Name: trade name depends on the source of the product
Pharmaceutical Form: Suspension for injection in pre-filled syringe
INN or Proposed INN: LEUPRORELIN ACETATE
CAS Number: 74381-53-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 30-
Abbvie previously known as AbbottNot AvailableFemale: yes
Male: yes
72United States;Puerto Rico
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11EUCTR2014-004495-36-Outside-EU/EEA1 December 2014A study of Lupron Depot Lupron Depot in treatment of central premature pubertyStudy of Lupron Depot in the Treatment of Central Precocious PubertyCentral Precocious Puberty
MedDRA version: 17.1 Level: LLT Classification code 10073186 Term: Central precocious puberty System Organ Class: 100000004860 ;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Trade Name: trade name depends on the source of the product
Pharmaceutical Form: Suspension for injection in pre-filled syringe
INN or Proposed INN: LEUPRORELIN ACETATE
CAS Number: 74381-53-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 7.5-
Trade Name: trade name depends on the source of the product
Pharmaceutical Form: Suspension for injection in pre-filled syringe
INN or Proposed INN: LEUPRORELIN ACETATE
CAS Number: 74381-53-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 15.0-
Abbvie previously known as AbbottNot AvailableFemale: yes
Male: yes
55United States
12NCT02920515September 201210 October 2016Study of Comprehensive Diagnosis and Treatment for Children Precocious PubertyMulti-site Study of Comprehensive Treatment for Children Precocious PubertyCentral Precocious PubertyDrug: Triptorlin or Leuprorelin;Drug: Zhibo dihuang pills;Drug: Dabu ying pillsRuijin HospitalShanghai Children's Hospital;Shanghai Children's Medical Center;Xin Hua Hospital;Shanghai Children's Hospital;Shanghai Children's Medical Center;Xin Hua HospitalNot recruiting2 Years14 YearsFemale740Phase 4
13NCT01467882April 201216 December 2017Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious PubertyAn Open-label, Non-comparative, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Triptorelin Pamoate (Embonate) 22.5 mg 6-month Formulation in Patients Suffering From Central (Gonadotropin-dependent) Precocious PubertyCentral Precocious PubertyDrug: TriptorelinDebiopharm International SANot recruiting2 Years9 YearsAll44Phase 3United States;Chile;Mexico
14NCT01634321July 201119 February 2015The Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Acetate 3.75mg) in Patients With Precocious PubertyThe Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Acetate 3.75mg) in Patients With Precocious Puberty; A Single, Open, Multi-center, Prospective StudyCentral Precocious PubertyDrug: Luphere depot 3.75mg(Leuprolide acetate 3.75mg)Daewoong Pharmaceutical Co. LTD.Not recruiting4 Years9 YearsBoth63Phase 4Korea, Republic of
15NCT01278290July 201019 February 2015Comparative Validation of the Triptorelin Test for the Diagnosis of CPP in GirlsTriptorelin Acetate Utilization for the Early Diagnosis of Central Precocious Puberty (CPP) in Girls.Central Precocious Puberty;Sexual PrecocityDrug: Triptorelin acetate and Gonadorelin acetate;Drug: Gonadorelin acetate and Triptorelin acetateHospital de Niños R. Gutierrez de Buenos AiresNot recruiting3 Years8 YearsFemale40Phase 4Argentina
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16NCT00667446December 200819 October 2017Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious PubertyA 36 Month, Multi-Center, Open-Label Extension Study to Evaluate the Safety of Leuprolide Acetate 11.25 mg and 30 mg Formulations in Children With Central Precocious PubertyPrecocious;Leuprolide Acetate;Luteinizing Hormone (LH);Gonadotrophin-releasing Hormone Agonist (GnRHa);Tanner Staging;Depot Formulation;Suppression of LH;Central Precocious Puberty (CPP);Gonadotrophin-releasing Hormone (GnRH);Lupron;GnRH Analog;Pediatrics Central Precocious PubertyDrug: Leuprolide Acetate 3 Month DepotAbbVie (prior sponsor, Abbott)Not recruitingN/AN/AAll72Phase 3United States;Puerto Rico
17NCT00635817June 200819 October 2017A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious PubertyA Phase 3, Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy and Safety of Leuprolide Acetate 11.25 and 30 mg Formulations in Children With Central Precocious PubertyPuberty, PrecociousDrug: Leuprolide acetate 11.25 mg;Drug: Leuprolide acetate 30 mgAbbottNot recruiting2 Years11 YearsAll84Phase 3United States;Puerto Rico
18NCT00438217May 200619 February 2015Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty ChildrenAnalysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty ChildrenCentral Precocious PubertyDrug: Triptorelin (GnRH agonists);Drug: Leuprolide (GnRH agonists)University of PisaRecruiting1 Year18 YearsBoth100Phase 4Italy
19NCT00779103September 200429 June 2015Histrelin Subcutaneous Implant in Children With Central Precocious PubertyPhase III, Open-Label Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Children With Central Precocious PubertyCentral Precocious PubertyDrug: Histrelin Subcutaneous ImplantEndo PharmaceuticalsNot recruiting2 Years10 YearsBoth36Phase 3
20NCT00660010January 199119 October 2017Study of Lupron Depot In The Treatment of Central Precocious PubertyStudy of Lupron Depot In The Treatment of Central Precocious PubertyPuberty, PrecociousDrug: Lupron (leuprolide acetate)AbbottNot recruitingN/A10 YearsAll55Phase 3United States

先頭へ